Further validation may establish AQP3 and AQP5 as additional prognostic biomarkers for pancreatic cancer, potentially contributing to improving early disease detection, prognosis, and personalized treatment strategies. This evidence concerns the gene AQP5 and familial pancreatic carcinoma.